Obesity is associated with advanced prostate cancer and poorer prognosis, driven by systemic and local inflammation that alters the tumor immune microenvironment.
Do interventions to control inflammation and lifestyle changes improve prognosis in obese men with prostate cancer?
Obesity-induced systemic and local inflammation plays a key role in prostate cancer progression, suggesting anti-inflammatory and lifestyle interventions as potential therapies.
The prevalence of obesity is increasing in the world, and obesity-induced disease, insulin-resistance, cardiovascular disease, and malignancies are becoming a problem. Epidemiological studies have shown that obesity is associated with advanced prostate cancer and that obese men with prostate cancer have a poorer prognosis. Obesity induces systemic inflammation via several mechanisms. High-fat diet-induced prostate cancer progresses via adipose-secretory cytokines or chemokines. Inflammatory cells play important roles in tumor progression. A high-fat diet or obesity changes the local profile of immune cells, such as myeloid-derived suppressor cells and macrophages, in prostate cancer. Tumor-associated neutrophils, B cells, and complements may promote prostate cancer in the background of obesity. Interventions to control systemic and/or local inflammation and changes in lifestyle may also be viable therapies for prostate cancer.
Fujita et al. (Wed,) conducted a review in Prostate cancer and obesity. Obesity and high-fat diet was evaluated. Obesity is associated with advanced prostate cancer and poorer prognosis, driven by systemic and local inflammation that alters the tumor immune microenvironment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: